Myriad Genetics - MYGN Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View MYGN analyst ratings or view top-rated stocks.

4 analysts have issued 1-year price objectives for Myriad Genetics' stock. Their MYGN share price forecasts range from $23.00 to $32.00. On average, they predict the company's stock price to reach $26.20 in the next year. This suggests a possible upside of 12.8% from the stock's current price.
View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts.

Myriad Genetics' stock was trading at $14.51 at the start of the year. Since then, MYGN shares have increased by 60.1% and is now trading at $23.23.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our MYGN earnings forecast.

Myriad Genetics, Inc. (NASDAQ:MYGN) released its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.02). The company earned $167.30 million during the quarter, compared to analyst estimates of $164.35 million. Myriad Genetics had a negative net margin of 16.51% and a negative trailing twelve-month return on equity of 5.83%. During the same period in the prior year, the business earned ($0.19) earnings per share.

ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Psyk Etf (PSYK), Global X Genomics & Biotechnology ETF (GNOM), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Myriad Genetics issued an update on its first quarter 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of -$0.20--$0.18 for the period, compared to the consensus EPS estimate of -$0.10. The company issued revenue guidance of $170.00 million-$172.00 million, compared to the consensus revenue estimate of $174.88 million.

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MYGN stock can currently be purchased for approximately $23.23.

Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.89 billion and generates $678.40 million in revenue each year. The company earns $-112,000,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

The company employs 2,600 workers across the globe.

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640.